7/25/2022 7:32:47 AM
Soligenix To Supply Ricin Antigen To SERB For Development Of Novel Therapeutic Treatment Against Ricin Toxin Poisoning
7/14/2022 7:16:18 AM
SERB Pharma Inks Worldwide License To Use An Antigen From Soligenix To Develop Ricin Antidote
6/28/2022 7:36:56 AM
Soligenix Gets FDA IND Clearance For Phase 2 Clinical Trial Of Synthetic Hypericin In Psoriasis
6/23/2022 7:34:01 AM
Soligenix:Bivalent Vaccine Provides 100% Protection In Non-human Primates Against Sudan Ebolavirus &Marburg Marburgvirus
5/23/2022 7:32:34 AM
Soligenix Receives US Patent Allowance For Thermostabilized Vaccine Platform
5/13/2022 7:39:30 AM
Soligenix March Quarter Revenues $0.2 Mln Vs. $0.1 Mln Prior Year
4/19/2022 7:38:08 AM
Soligenix Gets $1.4 Mln In Non-Dilutive Government Funding
3/29/2022 7:32:59 AM
Soligenix FY Net Loss $12.6 Mln Or $0.31/shr Vs. Loss $17.7 Mln Or $0.64/shr Prior Year
3/17/2022 7:33:34 AM
Soligenix Says COVID-19 Vaccine, CiVax, Boosts Neutralizing Activity Against SARS-CoV-2, Incl Delta And Omicron
1/4/2022 7:37:40 AM
Soligenix : Dusquetide Shows Positive Anti-tumor Efficacy In Multiple Nonclinical Animal Studies; Stock Up
11/12/2021 7:35:28 AM
Soligenix Q3 Revenues $0.2 Mln Vs. $0.6 Mln Prior Year
11/8/2021 7:33:03 AM
Soligenix Granted Pediatric Investigational Plan Waiver For HyBryte In CTCL In United Kingdom